What, Where, When and How of COVID-19 Patents Landscape: A Bibliometrics Review

Frontiers in Medicine

article

Kunmeng Liu¹  Xiaoming Zhang³  Yuanjia Hu⁴  Weijie Chen⁴  Xiangjun Kong⁴  Peifen Yao⁴  Jinyu Cong¹  Huali Zuo⁵  Jian Wang⁶  Xiang Li¹  Benzheng Wei¹ 

[1] Center for Medical Artificial Intelligence, Shandong University of Traditional Chinese Medicine;Qingdao Academy of Chinese Medical Sciences, Shandong University of Traditional Chinese Medicine;Department of Cardiovascular Surgery, The Affiliated Hospital of Qingdao University;State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau;Warshel Institute for Computational Biology, The Chinese University of Hong Kong;Science College, Shandong Jiaotong University

关键词: patent landscape;    patent mining;    bibliometric patent analysis;    social network analysis;    citation network;    COVID-19;    coronavirus;   

DOI  :  10.3389/fmed.2022.925369

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Two years after COVID-19 came into being, many technologies have been developed to bring highly promising bedside methods to help fight this epidemic disease. However, owing to viral mutation, how far the promise can be realized remains unclear. Patents might act as an additional source of information for informing research and policy and anticipating important future technology developments. A comprehensive study of 3741 COVID-19-related patents (3,543 patent families) worldwide was conducted using the Derwent Innovation database. Descriptive statistics and social network analysis were used in the patent landscape. The number of COVID-19 applications, especially those related to treatment and prevention, continued to rise, accompanied by increases in governmental and academic patent assignees. Although China dominated COVID-19 technologies, this position is worth discussing, especially in terms of the outstanding role of India and the US in the assignee collaboration network as well as the outstanding invention portfolio in Italy. Intellectual property barriers and racist treatment were reduced, as reflected by individual partnerships, transparent commercial licensing and diversified portfolios. Critical technological issues are personalized immunity, traditional Chinese medicine, epidemic prediction, artificial intelligence tools, and nucleic acid detection. Notable challenges include balancing commercial competition and humanitarian interests. The results provide a significant reference for decision-making by researchers, clinicians, policymakers, and investors with an interest in COVID-19 control.

【 授权许可】

CC BY